Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring EGFR exon 20 mutations
OncoTargets and Therapy. 2016;Volume 9:4181-4186 
EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications
The Lancet Oncology. 2012;13(1):e23-e31
Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer
Signal Transduction and Targeted Therapy. 2019;4(1):
Osimertinib for Chinese advanced non-small cell lung cancer patients harboring diverse EGFR exon 20 insertion mutations
Lung Cancer. 2021;152:39-48
Effectiveness of Treatments for Advanced Non–Small-Cell Lung Cancer With Exon 20 Insertion Epidermal Growth Factor Receptor Mutations
Clinical Lung Cancer. 2019;20(6):e620-e630
Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea
Cancer Research and Treatment. 2019;51(2):623-631
EFFECTIVENESS OF TREATMENTS IN ADVANCED NON-SMALL CELL LUNG CANCER WITH EXON 20 INSERTION EPIDERMAL GROWTH FACTOR RECEPTOR MUTATIONS
Respirology. 2018;23:168-168
EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins
Cancer Treatment Reviews. 2020;90:102105
Differences among lesions with exon 19, exon 21 EGFR mutations and wild types in surgically resected non-small cell lung cancer
Scientific Reports. 2016;6(1):
Comment on: ‘Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer’
Lung Cancer. 2020;148:179-180